An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects With Leukocyte Adhesion Deficiency Type II
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- AUG Therapeutics
- Study ID
- NCT05754450
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Leukocyte Adhesion Deficiency
Eligibility Criteria
- Sex
- ALL
- Age
- 6 Months - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- AVTX-803 — DRUGL-fucose crystalline powder
Study Details
The primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
Key Dates
- Start date
- Apr 10, 2023
- Status verified
- Apr 2026
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
Study Design
- Enrollment
- 2 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AVTX-803AVTX-803 at a dose specified by the investigator up to 5 times a day not to exceed 1700 mg/kg/day
Primary Outcome Measure
Incidence of treatment emergent adverse events reported during the study attributable to AVTX-803. [ Time Frame: Through study completion, an average of 1 year. ]
Central Contacts
- Jennifer Lin3052833827
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Queenie Tan, MD PhD |
Find similar trials in Rochester, MN
By research site
Related Studies
- A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type IIPHASE3 · Recruiting · AUG Therapeutics · Rochester, Minnesota